Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://markets.businessinsider.com/news/stocks/alert-to-longterm-investors-of-the-scotts-miraclegro-company-smg-grabar-law-office-is-investigating-claims-on-your-behalf-1033562551
WHAT YOU CAN DO NOW: Current Scotts shareholders who have held Scotts shares since on or before November 1, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/Scotts-Shareholder-Investigation/, contact Joshua Grabar at jgrabar @FH-6085.
Attorney Advertising Disclaimer
Cheers.
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/
Current Inari Medical, Inc. (NASDAQ: NARI) shareholders who have held since at least February 24, 2022, can seek corporate reforms, the return of funds back to company, and a court approved incentive, at no cost to them whatsoever. Click here: https://grabarlaw.com/the-latest/inari-shareholder-investigation/.
Grabar Law Office is investigating whether the Board of Directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) ("iRhythm") breached their fiduciary duties to shareholders.
If you have held iRhythm shares since prior to January 11, 2022, learn more at https://grabarlaw.com/the-latest/irhythm-shareholder-investigation/, or call Joshua H. Grabar at 267-507-6085.
Current Cutera, Inc. (NASDAQ: CUTR) shareholders who have held shares since at least March 1, 2022, can seek corporate reforms, the return of funds back to company, and a court approved incentive if appropriate, at no cost whatsoever. Click here: https://grabarlaw.com/the-latest/cutera-shareholder-investigation/.
Current Luna Innovations Incorporated (NASDAQ: LUNA) shareholders who have held shares of the Company's stock since at least May 16, 2022, have standing to seek corporate reforms, the return of funds back to company coffers and potentially a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more: https://grabarlaw.com/the-latest/luna-shareholder-investigation/. $LUNA
NOTICE TO LONG-TERM SHAREHOLDERS OF CUMMINS INC. (NYSE: CMI): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF
Current Cummins Inc. (NYSE: CMI) shareholders who have held Cummins shares since prior to April 30, 2019, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. To participate or learn more at no cost to you visit: https://grabarlaw.com/the-latest/cummins-shareholder-investigation/
Grabar Law Office is investigating claims on behalf of Cummins shareholders. The investigation concerns whether certain officers and directors of Cummins have breached their fiduciary duties owed to the company.
Why: On January 10, 2024, the Department of Justice and State of California announced that diesel engine manufacturer Cummins agreed to pay a record $1.675 billion civil penalty for vehicle emissions test cheating.
In addition, a securities fraud class action complaint has been filed that further alleges that Cummins, via certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that: (1) Contrary to its post-April 2019 Announcement assurances about its commitment to compliance, Cummins continued to produce engines with unlawful emission defeating devices from 2019 to 2023; (2) accordingly, Cummins understated its legal and regulatory risk, and overstated its commitment to environmental protection; and (3) as a result, Cummins’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
NOTICE: GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF LONG-TERM SHAREHOLDERS OF DICK’S SPORTING GOODS, INC. (NYSE: DKS)
Current Dick’s Sporting Goods, Inc. (NYSE: DKS) shareholders who have held Dick’s shares since on before May 25, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Click here https://grabarlaw.com/the-latest/dicks-shareholder-investigation/ to learn more or join.
Grabar Law Office is investigating claims on behalf of long-term Dick’s shareholders. The investigation concerns whether certain officers and directors of Dick’s have breached the fiduciary duties they owed to the company.
Why? A recently filed securities fraud class action complaint alleges that Dick’s Sporting Goods, Inc., (NYSE: DKS) through certain of its officers and directors, made false and/or misleading statements and/or failed to disclose that: (i) demand for products in Dick’s Outdoor segment was slowing faster than Defendants represented, resulting in excess inventory; (ii) the “structural changes” that Defendants repeatedly touted, including differentiated products, improved pricing technology, and more efficient clearance channels, did not allow the Company to manage its excess inventory without hurting the Company’s profitability; (iii) the need to liquidate excess inventory, including in the Outdoor segment, would have a materially negative effect on the Company’s profitability; and (iv) as a result of (i)-(iii) above, Defendants’ statements about Dick’s business condition and prospects were materially false and misleading when made.
What you can do now: Current Dick’s shareholders who have held Dick’s shares since prior to May 25, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/dicks-shareholder-investigation/, or contact Joshua H. Grabar at jgrabar @FH-6085.
Notice to Long-Term Shareholders of Mercury Systems, Inc. (MRCY): Grabar Law Is Investigating Claims on Your Behalf
If you have held $MRCY shares since prior to December 7, 2020, and want to learn more or join click here: https://grabarlaw.com/the-latest/mercury-systems-shareholder-investigation/ #MRCY #MercurySystems
ATTENTION LONG-TERM DOCGO INC. (NASDAQ: DCGO) SHAREHOLDERS: GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF
Grabar Law Office is investigating claims on behalf of DocGo Inc. (NASDAQ: DCGO) shareholders. The investigation concerns whether certain officers and directors of DocGo have breached their fiduciary duties owed to the company as, on April 10th the New York City Mayor's office said that the mobile health services provider's $432M no-bid migrant services contract will not be renewed before it expires on May 5. Instead, the officials plan to issue a competitive request to select a new provider by year-end.
Current DocGo Inc. (NASDAQ: DCGO) shareholders who have held DocGo shares since on or before November 8, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Click: https://grabarlaw.com/the-latest/docgo-shareholder-investigation/.
An underlying securities fraud class action complaint was filed after the New York City's Comptroller announced that it was commencing a real-time audit of operations and invoices incurred by DocGo as the Comptroller had “serious concerns about the selection of this vendor and its performance of contract duties.”
On April 10, 2024, The New York City Mayor's office announced that the mobile health services provider's $432M no-bid migrant services contract will not be renewed before it expires on May 5. Instead, the officials plan to issue a competitive request to select a new provider by year-end.
DocGo share prices are down approximately 70% from previous trading highs.
If you would like to learn more about this matter, you are encouraged visit https://grabarlaw.com/the-latest/docgo-shareholder-investigation/, email Joshua Grabar at jgrabar @FH-6085.
$DCGO #DocGo
NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.
Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.
If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.
Current long-term NYCB shareholders who have held NYCB shares since prior to March 1, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. See https://grabarlaw.com/the-latest/nycb-shareholder-investigation/
I am sure you are aware of the ongoing class action.
However, for longer term holders who still hold MPW shares (shareholders who have held Medical Properties Trust stock since on or before July 25, 2019), a few corporate governance actions have been filed. There is still room for more. Longer holders can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, visit https://grabarlaw.com/the-latest/mpw-shareholder-investigation/
A securities fraud class action complaint has been filed that alleges that New York Community Bancorp, Inc. (NYSE: NYCB), via certain of its officers and directors, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company was experiencing higher net charge-offs and deterioration in its office portfolio; (2) that, as a result, NYCB was reasonably likely to incur higher loan losses; (3) that, as a result of the foregoing and NYCB’s status as Category IV bank, the Company was reasonably likely to increase its allowance for credit losses; (4) that the Company’s financial results would be adversely affected; (5) that, to preserve capital, the Company would reduce quarterly common dividend to $0.05 per common share; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Current NYCB shareholders who have held NYCB shares since prior to March 1, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.
https://grabarlaw.com/the-latest/nycb-shareholder-investigation/
https://grabarlaw.com/the-latest/bioxcel-shareholder-investigation/
A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain officers and directors, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the complaint alleges Defendants failed to disclose to investors: (1) that the Company lacked adequate internal controls over protocol adherence and data integrity; (2) that, as a result, the Company’s principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) that the Company’s principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) that the Company’s principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) that the foregoing would negatively impact the Company’s ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer’s disease; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Current BioXcel shareholders who have held BioXcel stock since prior to December 15, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.
There is both a class action and a shareholder governance action.
The class action is brought on behalf of all persons or entities that purchased or otherwise acquired Sotera common stock: (i) pursuant and/or traceable to the Company’s initial public offering conducted on or around November 20, 2020 (the “IPO”); (ii)
pursuant and/or traceable to the Company’s secondary public offering conducted on or around March 18, 2021 (the “SPO,” and together with the IPO, the “Offerings”); and/or (iii) between November 20, 2020 and September 19, 2022, inclusive (the “Class Period”). This action is to recover damages.
On the governance action: Current long-term Sotera shareholders who have held Sotera stock: (i) pursuant and/or traceable to the Company’s initial public offering conducted on or around November 20, 2020 (the “IPO”) or (ii) pursuant and/or traceable to the Company’s secondary public offering conducted on or around March 18, 2021 can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to contact at jgrabar @FH-6085.
A recently filed securities fraud class action alleges that Beyond Meat (NASDAQ: BYND), through certain officers and directors, made material misrepresentations and omissions concerning the Company’s ability to produce plant-based meats at scale to the specifications of its key customers, who the Company refers to as “partners.”
It is alleged that Beyond Meat misled investors by boasting about the success of its product tests with its large-scale partnerships, including prominent food retailers like McDonalds, Starbucks, KFC, Pizza Hut, and Taco Bell. Beyond Meat assured investors and partners that it would “ensure manufacturability” through “extensive testing,” and that it was capable of manufacturing the unique plant-based meat products at commercial scale. Further, Beyond Meat blamed any delays in launching these large-scale partnerships on Covid-19.
Certain Beyond Meat executives profited enormously from this scheme by selling hundreds of thousands of shares of their personally held Company stock at artificially inflated prices during the Class Period. For instance, Defendant Nelson sold 440,000 shares of Beyond Meat stock during the Class Period for over $58.3 million in proceeds.
The truth began to emerge on October 22, 2021, when Beyond Meat announced that the Company was reducing its third quarter net revenues outlook by up to $34 million, or 25%. As part of the announcement, Beyond Meat also revealed that the Company’s expenses and inventories were continuing to rise. As a result of these disclosures, the price of Beyond Meat stock declined by $12.82 per share, or nearly 12%, from $108.62 per share to $95.80 per share.
Then, on November 10, 2021, Beyond Meat announced a $1.8 million write-off of unsold inventory. As a result of this disclosure, the price of Beyond Meat stock declined by $12.55 per share, or nearly 13%, from $94.48 per share to $81.93 per share.
However, Beyond Meat continued to assure investors of the success of its partnerships. For example, on November 10, 2021, Defendant Brown claimed that the Company “overcame numerous technical challenges” and blamed its poor financial results on the Covid-19 pandemic.
Then, on November 17, 2021, an article was published in Bloomberg highlighting the delays in production and execution challenges Beyond Meat was facing. Former employees reported that there were “significant internal problems” stemming from “confusion and misalignment . . . [and] belated decision-making” that corresponded with exacerbated production delays. As a result of these disclosures, the price of Beyond Meat stock declined by $3.01 per share, or more than 3.5%, from $83.48 per share to $80.97 per share.
On December 9, 2021, after the market closed, multiple media sources reported that Taco Bell had cancelled a planned product test due to ongoing quality concerns. As a result of these disclosures, the price of Beyond Meat stock declined by $5.58 per share, or nearly 8%, from $70.09 per share to $64.51 per share.
On October 14, 2022, Beyond Meat announced the departure of several top executives, including the Company’s Chief Operating Officer, Chief Growth Officer, and Chief Financial Officer. As a result of these disclosures, the price of Beyond Meat stock declined by $1.43 per share, or over 9.6%, from $14.78 per share to $13.35 per share.
As a result of Defendants’ wrongful acts and omissions, and the resulting decline in the market value of Beyond Meat’s stock, Plaintiff and other Class members have suffered significant losses and damages.
https://grabarlaw.com/the-latest/beyond-meat-shareholder-investigation/
A securities fraud class action complaint alleges that Live Nation, via certain of its officers and directors, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the class action complaint alleges Defendants failed to disclose to investors: (1) that Live Nation engaged in anticompetitive conduct, including charging high fees and extended contracts with talent, and retaliated against venues; (2) that, as a result, Live Nation was reasonably likely to incur regulatory scrutiny and face fines, penalties, and reputational harm; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Current Live Nation shareholders who have held Live Nation stock since prior to February 23, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.
https://grabarlaw.com/the-latest/live-nation-shareholder-investigation/
A federal court has allowed a class action to proceed in which it is alleged
that certain of Paysign's officers made materially false and misleading
statements to the public as to Paysign's financial statements, which in turn
allowed certain officers to engage in insider trading of their Paysign shares
while the stock's prices were artificially inflated.
If you would like to learn more about this matter, you are encouraged to
contact us at jgrabar@grabarlaw.com, visit
https://grabarlaw.com/paysign-shareholder-litigation/, or call 267-507-6085.
https://stockhouse.com/news/press-releases/2023/08/21/grabar-law-office-investigates-claims-on-behalf-of-shareholders-of-ardelyx-inc
Community
Markets
News
Portfolio
DealRoom
Search Companies, etc
News Press Releases
Grabar Law Office Investigates Claims on Behalf of Shareholders of Ardelyx Inc. (ARDX)
ARDX | 9 minutes ago
Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2023) - A securities class action complaint alleges that Ardelyx Inc. (NASDAQ: ARDX), via certain of its officers, made materially false and misleading statements regarding tenapanor and the likelihood that it would be approved by the FDA, which led investors to suffer significant losses.
Specifically, it is alleged that on or about June 30, 2020, Ardelyx submitted a New Drug Application ("NDA") to the FDA to obtain approval to sell and market tenapanor for the treatment of hyperphosphatemia in adult CKD patients on dialysis. Because Defendants considered tenapanor their leading product candidate, the fate of Ardelyx's tenapanor NDA - i.e., whether the FDA would approve or reject it - was integral to the valuation and future success of Ardelyx securities.
Although Defendants repeatedly assured the market that the FDA's approval was all but guaranteed because the FDA had already seen some of the data and because the Company's meetings with the FDA were going well, in fact as early as March 2020 the FDA had raised substantial concerns that Ardelyx's clinical trial data had not shown a sufficiently quantifiable clinical benefit of administering tenapanor to treat hyperphosphatemia in adult CKD patients on dialysis. Then, on July 19, 2021, the Company announced that the FDA had rejected the tenapanor NDA for the exact reasons the FDA outlined in the March 2020 meeting.
Current Ardelyx shareholders who have held Ardelyx shares since on or before March 6, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to contact us at jgrabar@grabarlaw.com, visit https://grabarlaw.com/the-latest/ardelyx-shareholder-investigation/, or call 267-507-6085.
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA) F/K/A SOARING EAGLE ACQUISITION CORP. (NASDAQ: SRNG) AFTER SECURITIES FRAUD CLASS ACTION SURVIVES MOTION TO DISMISS
A federal securities class action complaint against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) F/K/A Soaring Eagle Acquisition Corp. (NASDAQ: SRNG) and certain of its officers has survived a motion to dismiss.
Current long-term Ginkgo shareholders who acquired shares via the Soaring Eagle SPAC, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.
https://grabarlaw.com/the-latest/ginkgo-bioworks-shareholder-investigation/
https://grabarlaw.com/the-latest/pilgrims-pride-shareholder-investigation/?fbclid=IwAR1EmTOh8fxZzqAVVupwTsY4bsA7PoFmUATOZfMQzt9uIKv5Hgb7dHvJQ7Y
Grabar Law Office is investigating potential claims on behalf of Pilgrim’s Pride Corp. (NASDAQ: PPC) shareholders. The investigation concerns whether certain officers and directors of Pilgrim’s Pride have breached their fiduciary duties owed to the company.
Pilgrim’s Pride has previously pled guilty to conspiring to fix the price of broiler chicken products and was sentenced to pay roughly $107.9 million in criminal fines. In related civil antitrust litigation Pilgrim's Pride has agreed to a $75 million settlement.
On February 9, 2022, Pilgrim’s Pride learned that the Department of Justice (“DOJ”) opened a civil investigation into human resources antitrust matters. Specifically, it has been reported that this investigation centers around whether Pilgrim’s Pride engaged in anticompetitive sharing about employment practices that held down plant workers’ wages.
On October 6, 2022, Pilgrim’s Pride learned that the DOJ opened a civil investigation into Pilgrim’s Pride’s grower contracts and payment practice. It is alleged that Pilgrim’s Pride illegally agreed to share detailed data on grower compensation with other processors, with the purpose and effect of artificially depressing compensation to growers.
Current long-term Pilgrim’s Pride shareholders may be able to seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award if appropriate.
Current Generac shareholders who have held Generac stock since before April 29, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
https://grabarlaw.com/the-latest/generac-shareholder-investigation/
In February 2020, the Company announced a partnership with Subway® restaurants to enable Subway’s more than 20,000 U.S.-based restaurants to handle digital orders from third-party “marketplaces” such as Uber Eats or DoorDash. Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
It is alleged that Olo, through certain of its officers, misled investors and/or failed to disclose that (1) Subway was ending its contract with Olo; (2) Olo’s key business metric – active locations – could not continue to grow as Defendants touted due to the loss of Subway’s business; and (3) that, as a result of the above, Defendants’ statements about Olo’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
Current Olo shareholders who have held Olo stock since before August 11, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
https://grabarlaw.com/the-latest/olo-shareholder-investigation/
Twist shareholders who have held company stock since before December 13, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.
https://grabarlaw.com/the-latest/twist-bioscience-shareholder-investigation/
It is alleged, in several class actions, that the Company and certain of its officers overstated the commercial viability of Twist Bioscience’s synthetic DNA manufacturing technology while engaging in accounting fraud and using unsustainable pricing to inflate Twist Bioscience’s true financial condition and prospects.
Unlike a class action, brought on behalf of investors, a shareholder derivative action or demand is brought by a shareholder of a public company on behalf of and for the benefit of the company itself. In a derivative action, shareholders “step into the shoes” of the directors and officers of a company and bring litigation that the board would be unwilling to pursue on its own. Shareholder derivative litigation can recover damages back to the company for financial or reputational harm caused by the conduct of its insiders, and also can be used to improve the governance of public companies in order to guard against such harms in the future.
Do you still hold TWST shares?
A securities fraud class action alleging wrongdoing committed by certain of 22nd Century Group, Inc’ Officers and Directors has survived a motion to dismiss the complaint.
https://grabarlaw.com/the-latest/22nd-century-shareholder-investigation/
A securities fraud class action alleging wrongdoing committed by certain of CleanSpark’s Officers and directors has survived a motion to dismiss the complaint. See https://grabarlaw.com/the-latest/cleanspark-shareholder-investigation/
Visit https://events.benzinga.com/nic-webinar-v31666966753513
Grabar Law Office Investigates Claims on Behalf of Shareholders of Silvergate Capital Corporation (SI)
by
Newsfile
January 6, 2023 5:23 PM | 1 min read
FREE REPORT: Click to Get the Benzinga Pro Insider report (no credit card needed)
Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - According to a recently filed shareholder complaint, Silvergate Capital Corporation a digital currency company, and certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, it is alleged that the Company and its officers failed to disclose that the Company's platform lacked sufficient controls and procedures to detect instances of money laundering such that Silvergate's customers had engaged in money laundering in amounts exceeding $425 million and, as a result, Silvergate was likely to receive regulatory scrutiny and face damages.
If you are a current Silvergate shareholder who has held the stock since at least November 9, 2021, you may be able seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award.
If you would like to learn more about this matter at no cost to you, visit https://grabarlaw.com/the-latest/silvergate-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.
Peabody securities class action settlement has been preliminarily approved:
https://grabarlaw.com/the-latest/peabody-energy-investigation/
https://www.wsj.com/articles/shareholder-alert-grabar-law-office-investigates-potential-claims-on-beahlf-of-shareholders-of-peabody-energy-corporation-btu-01670937502
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF BED BATH & BEYOND INC. (NASDAQ: BBBY)
If you have held Bed Bath & Beyond shares since on or before March 1, 2022, you may be able seek corporate reforms, the return of funds expended defending litigation back to company coffers, and potentially a court approved incentive award if appropriate.
If you would like to learn more about this matter at no cost to you, visit https://grabarlaw.com/the-latest/bed-bath-beyond-shareholder-derivative-investigation/, contact us at jgrabar@grabarlaw.com or call 267-507-6085. $BBBY
Do you hold APPS as a long holder?